HK1004525A1 - Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a - Google Patents

Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a

Info

Publication number
HK1004525A1
HK1004525A1 HK98103623A HK98103623A HK1004525A1 HK 1004525 A1 HK1004525 A1 HK 1004525A1 HK 98103623 A HK98103623 A HK 98103623A HK 98103623 A HK98103623 A HK 98103623A HK 1004525 A1 HK1004525 A1 HK 1004525A1
Authority
HK
Hong Kong
Prior art keywords
herpes simplex
monophosphoryl lipid
deacylated monophosphoryl
hsv glycoprotein
simplex vaccine
Prior art date
Application number
HK98103623A
Other languages
English (en)
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Garcon-Johnson
Claude Marie-Josephe
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1004525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HK1004525A1 publication Critical patent/HK1004525A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
HK98103623A 1991-03-21 1998-04-28 Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a HK1004525A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine
PCT/EP1992/000592 WO1992016231A1 (en) 1991-03-21 1992-03-17 HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (1)

Publication Number Publication Date
HK1004525A1 true HK1004525A1 (en) 1998-11-27

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103623A HK1004525A1 (en) 1991-03-21 1998-04-28 Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a

Country Status (34)

Country Link
US (1) US6027730A (pt)
EP (1) EP0576478B2 (pt)
JP (1) JP3530526B2 (pt)
KR (1) KR100224329B1 (pt)
CN (2) CN1058191C (pt)
AP (1) AP298A (pt)
AT (1) ATE129160T1 (pt)
AU (1) AU650521B2 (pt)
BR (1) BR9205745A (pt)
CA (1) CA2106492C (pt)
CY (1) CY1936A (pt)
CZ (1) CZ280505B6 (pt)
DE (1) DE69205566T3 (pt)
DK (1) DK0576478T4 (pt)
ES (1) ES2081102T5 (pt)
FI (1) FI107881B (pt)
GB (1) GB9105992D0 (pt)
GR (1) GR3017884T3 (pt)
HK (1) HK1004525A1 (pt)
HU (1) HU218025B (pt)
IE (1) IE69560B1 (pt)
IL (1) IL101290A (pt)
MA (1) MA22471A1 (pt)
MX (1) MX9201245A (pt)
MY (1) MY110086A (pt)
NO (1) NO307499B1 (pt)
NZ (1) NZ242057A (pt)
PL (1) PL170059B1 (pt)
PT (1) PT100262B (pt)
SA (1) SA92120459B1 (pt)
SK (1) SK279190B6 (pt)
WO (1) WO1992016231A1 (pt)
YU (1) YU28392A (pt)
ZA (1) ZA922011B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
WO1994027636A1 (en) * 1993-05-25 1994-12-08 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU717779C (en) * 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
EP1797896A1 (en) 1998-10-16 2007-06-20 GlaxoSmithKline Biologicals SA Adjuvant systems and vaccines
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
US20080181911A1 (en) 2005-03-23 2008-07-31 Emmanuel Jules Hanon Use Of An Influenza Virus, An Oil-In-Water Emulsion Adjuvant, To Induce Cd4 T-Cell And/Or Improved B-Memory Cell Response
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
MY159500A (en) * 2009-05-22 2017-01-13 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102666843B (zh) * 2009-12-21 2014-10-22 布里格海姆妇女医院公司 单纯疱疹病毒疫苗
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN103619350A (zh) * 2011-03-11 2014-03-05 麦克马斯特大学 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
EP2747779A4 (en) 2011-08-22 2015-04-08 Nanobio Corp VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
ES2787455T3 (es) 2012-05-16 2020-10-16 Immune Design Corp Vacunas para el VHS-2
EP2941269B1 (en) 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutic vaccines for treating herpes simplex virus type 2 infections
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0289550B1 (en) * 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
DE69131984T2 (de) * 1990-08-01 2000-07-06 Res Corp Technologies Inc Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
DE69131200T2 (de) * 1990-08-02 1999-12-09 Chiron Corp Herpes simplex virus vp16 impfstoffe
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
SG90042A1 (en) * 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1994021292A1 (en) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
WO1994027636A1 (en) * 1993-05-25 1994-12-08 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
SA92120459B1 (ar) 2005-06-14
CN1065997A (zh) 1992-11-11
NZ242057A (en) 1993-12-23
CY1936A (en) 1992-03-17
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
ES2081102T5 (es) 2001-09-01
FI934134A (fi) 1993-09-21
PL170059B1 (pl) 1996-10-31
KR100224329B1 (ko) 1999-10-15
JP3530526B2 (ja) 2004-05-24
WO1992016231A1 (en) 1992-10-01
IL101290A (en) 1996-07-23
DE69205566D1 (en) 1995-11-23
MX9201245A (es) 1992-10-01
DE69205566T3 (de) 2002-09-05
DE69205566T2 (de) 1996-04-18
ES2081102T3 (es) 1996-02-16
NO933343D0 (no) 1993-09-20
EP0576478B2 (en) 2001-04-18
AP298A (en) 1994-01-14
PT100262A (pt) 1993-06-30
MA22471A1 (fr) 1992-10-01
CZ280505B6 (cs) 1996-02-14
PT100262B (pt) 2001-05-31
US6027730A (en) 2000-02-22
CN1201692A (zh) 1998-12-16
HUT67052A (en) 1995-01-30
ZA922011B (en) 1993-01-27
CZ195893A3 (en) 1994-07-13
CA2106492A1 (en) 1992-09-22
IL101290A0 (en) 1992-11-15
DK0576478T3 (da) 1995-12-04
JPH06505727A (ja) 1994-06-30
NO933343L (no) 1993-09-20
FI934134A0 (fi) 1993-09-21
EP0576478A1 (en) 1994-01-05
YU28392A (sh) 1994-11-15
CN1058191C (zh) 2000-11-08
SK94693A3 (en) 1994-05-11
SK279190B6 (sk) 1998-07-08
DK0576478T4 (da) 2001-07-23
MY110086A (en) 1997-12-31
BR9205745A (pt) 1994-10-18
HU9302645D0 (en) 1994-01-28
IE69560B1 (en) 1996-10-02
AP9200368A0 (en) 1992-04-30
GB9105992D0 (en) 1991-05-08
IE920881A1 (en) 1992-09-23
HU218025B (hu) 2000-05-28
FI107881B (fi) 2001-10-31
AU650521B2 (en) 1994-06-23
CN1101226C (zh) 2003-02-12
ATE129160T1 (de) 1995-11-15
GR3017884T3 (en) 1996-01-31
NO307499B1 (no) 2000-04-17
EP0576478B1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
HK1004525A1 (en) Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
SG48375A1 (en) Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
SG48309A1 (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9106048D0 (en) Vaccines
EP0241655A3 (en) Extended raster operating in a display system
EP0537021A3 (en) Camera-calibration in a computer vision system
GB2264606B (en) Image stability in telecines
GB2275401B (en) A graphic coloring system in a graphic display system
GB8913152D0 (en) 3-d image and sign system
AU2968892A (en) Vaccines based on modified type 1 bovine herpesviruses
ZA924670B (en) Ccv vaccine
GB9114714D0 (en) Herpesvirus vaccine
ZA923273B (en) Herpesvirus particles and vaccine
GB9106152D0 (en) Free-standing greetings card display unit
GB9212816D0 (en) Vaccines and their uses
GB9002545D0 (en) 3-d image and sign system
GB9204320D0 (en) Herpesvirus particles and vaccine
ZA928770B (en) Vaccines
GB9105993D0 (en) Vaccines
GB9110067D0 (en) Vaccines
GB9119009D0 (en) Vaccines
GB9121208D0 (en) Vaccines
GB9116065D0 (en) Sheet delivery system

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120316